LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Certara to Participate in Upcoming Investor Conferences

August 31, 2021 | Last Trade: US$16.73 0.20 1.21

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:

  • Morgan Stanley 19th Annual Global Healthcare Conference
    Date and Time: Tuesday, September 14 at 9:30 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer
  • Baird 2021 Global Healthcare Conference
    Date and Time: Wednesday, September 15 at 4:55 p.m. ET
    Speaker: Andrew Schemick, chief financial officer
  • Bank of America Securities 2021 Tech Solutions for Drug Discovery Conference
    Date and Time: Monday, September 20 at 8:00 a.m. ET
    Speakers: William Feehery, chief executive officer, and Andrew Schemick, chief financial officer

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB